NCT05247957

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Hangzhou Cheetah Cell Therapeutics Co., Ltd · Academic / Other
• Sex: All
• Age: 10 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial will explore the maximum tolerated dose of cord blood NKG2D CAR-NK in the treatment of recurrent refractory acute myeloid leukemia in a dose-escalation manner, and observe its clinical safety and efficacy.

Detailed description

This is a single arm, open-label, Phase 1 study initiated with 3 cohorts: Cohort 1: 2×10∧6/kg CAR-NK cells, 2 infusions on Day 0 and Day 7 Cohort 2: 6×10∧6/kg CAR-NK cells, 2 infusions on Day 0 and Day 7 Cohort 3: 18×10∧6/kg CAR-NK cells, 2 infusions on Day 0 and Day 7

Conditions

• Safety and Efficacy

Interventions

Type	Name	Description
BIOLOGICAL	CAR-NK cells	NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7

Timeline

• Start date: 2021-10-13
• Primary completion: 2022-12-12
• Completion: 2022-12-20
• First posted: 2022-02-21
• Last updated: 2023-01-13

Locations

1 site across 1 country: China